IPHA - Earnings call transcript Q4 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen and welcome to the Innate Pharma’s Full Year 2021 Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I will now hand over to Mr. Henry Wheeler, Head of Investor Relations of Innate Pharma to begin. Sir, please go ahead.

Henry Wheeler

you. Thank afternoon good welcome and morning, everyone. Good Innate update for morning, issued results. a business a providing release the press This XXXX year full We future the as presenting look during forward year-to-date the progress well and goals made addressing plans. as to are The available IR on website. both press the today’s of the and release presentation section product to X, the addition in financial like that plan will remind and development. Slide On would make we outlook, to you I forward-looking regarding regulatory statements results uncertainties statements from to are actual subject may These differ and forecasted. that risks those cause to On Mondher on to today’s then Officer, joined Slide call, X, over we Mahjoubi, who be will Dr. hand Executive by our Chief will Joyson Karakunnel, Officer. our Medical and EVP Chief Mondher, [Technical will over hand I to you. Difficulty] now

Mondher Mahjoubi

Can well? hear me Henry. you, you Thank

Operator

I hear can well now. you

Mondher Mahjoubi

Perfect. Thank you.

our Slide strategy. Please me let So, move you X. first start reminding to by

our to centers we R&D efforts key priorities know, drive from where you partnership be sense stage three strategy it our while value around makes so. through early to look As later

proprietary by to look we Firstly, for T-cell in lead create lacutamab, lymphoma. value driven which is development our product significant candidate,

industry continue to across fuel our foundation multi-specific longer academia. strong for leveraging cell our by to focus leveraging called we engineering platform sustainable Last but partnerships primary various we and and ANKET. least, are pipeline Engager building capabilities the value innovative antibody term develop NK create on not and molecules our with Second, a our business,

offer plan we We product, as agreement gain to in is our that will of to for development to valuable much partner have product possible. time sure validate want we early our which consider we reinvest a goal that Our leverage the that and further value we competencies, capital the make our advance can as portfolio. will if can our

can deliver to first, strategic all the XXXX as a announced Starting to mycosis Let X of be with the lacutamab the where meeting earlier our pillars for busy at the advancement we have the progress I in in busy highlights stage and slide this next year across ICML strategic key XXXX. exciting slide. steady TELLOMAK. presented cover trial, demonstrated data we and very year was we Phase the continue Innate, on the objective seen to next me on where fungoides Lugano for will turn now

We also also in initiated on SITC see the indication were very R&D trials to the we presented lymphoma. last last at peripheral preclinical In entered agent larger year AML The the compound T-cell ANKET two lead into were data in pipeline, year. of CDXXX model clinic. by the tri-specific Sanofi pleased selected the targeted

we with tetra-specific So, presented continue data towards studies ANKET to throughout progress proprietary the our year. IND-enabling preclinical

to IPHXXXX adenosine look have IPHXXXX. Marseille we here Cancer and pathway our partnership we with with with steps trial our AstraZeneca on IPC Phase discussions in On the next front, our in X the initiated Center anti-CDXX for the further anti-CDXX

trial presentation setting the in in ESMO see cancer turn length AstraZeneca further PACIFIC-X, X we year, from monalizumab, with as Phase our NeoCOAST-X also trial meeting. lung from saw earlier AACR COAST for sitting we Phase to more we at resectable data the randomized expect last few and patient. At NeoCOAST-X weeks the the and in the study X pleased Stage Phase were we in very see X lung neoadjuvant to start device registrational trial, commence cancer on Finally, unresectable another called X to partner

at Finally, IO. move the durvalumab the from presented year, monalizumab, we as end of ESMO the next frontline triplet head and data of neck also may the slide. cancer Please remember, cetuximab combination in the to you and at

asset, our shows robust based how strategy we illustrates our It particular, we executing proprietary proprietary Before the from by our are also NK science in lacutamab, an I partner how hand platform. products, of cell is a translated into Engager and assets. lead early and over stage supported to overview Joyson, of against which portfolio here partnered with have our pipeline,

our pleased X/X pass we proprietary looks sales years made to forward throughout now couple data Joyson Phase in with progress of now Joyson, business. space to over our of as registrational X. the We the Phase are the please? see look asset. progress the would will the with to also create the our I R&D to with scientific portfolio potential engine to know-how starting like who and upcoming portfolio to multiple leverage And from a in clinical review sustainable readouts progressing catalysts most assets call lacutamab, advanced clinical to our the

Joyson Karakunnel

X, Thank that On targets KIRXDLX. our the receptor, immune antibody start first-in-class with me let Slide Mondher. you, humanized monoclonal

XX% you may T-cell approximately of for demonstrating As shown cutaneous To-date, certain and patients T-cell even aggressive single-agent more but is the prognosis expression advanced tissue. at with data lymphomas potential found promise, compelling activity inhibitory across in limited all an an and lymphomas subtypes, receptor which healthy options remember, in at few from are stage. with there lacutamab have therapeutic poor offering historically associated immense in KIRXDLX

fungoides diagnostic mycosis this syndrome of the was presented In we enrolled. also the our the The Today, KIRXDLX fungoides, mycosis the XXXX threshold X mycosis mycosis our XXXX. have next the evaluate TELLOMAK at in ongoing cohort expressing and clearing announcing X, companion FFPE cohort be all-comers a predetermined Phase before year X highlight also XX% and considered fungoides late-stage from Stage study fungoides. made me we an for mycosis are Let to setting moved to KIRXDLX in will cohort further the progress in data of data Stage being in for fungoides trials. Sézary Lugano was opening

data the this scientific the was cohort of X number and as to was to confirmed move per recruitment stopped. design expected, Stage the the by responses our into was reached in X-stage non-expressing not as As hypothesis cohort Simon

summary we preliminary the syndrome cohort, track KIRXDLX able showed Slide is a of data we Cohort Sézary X, In X response we On mycosis and to portion. have be preliminary to an the on XXXX. expect For enrollment report X expressors Cohort of in rate X, treatment results data patients with overall late-line XX% in in fungoides and of the non-expressors. Cohort limited

In As the median anticipate XX Even we have skin of of update. the confirmed on quality we the out life next out of skin confirmed have patients. the term follow-up, compartment follow-up because X.X its important for been months, XX with X the three responses. the is follow-up compartment, there the response presenting at of compartments, of short duration Of only association with XX is responses. longer

of non-expressors look you right X the As slide, the can data. the Cohort to see you

per this progress And the not the stopped. from as trial for this design to explained earlier, cohort, in X-stage non-expressing X the to to due As was Stage I anticipated Stage reached Simon required was three events recruitment X.

look further proof and let Slide XXXX. lacutamab. forward me We are by encouraged with X, points summarize the progress On making the to in we data are

pivotal T-cell fast-to-market prime the syndrome a We designation for U.S. and Fast underway was potentially trial lacutamab in setting strategy lymphomas, initial designation of last Sézary year. EU Track with a are pursuing in where lacutamab granted

have seen from to fungoides, past syndrome our data expanded Sézary trial. have We mycosis X where encouraging Phase we preliminary

of line X expressing be we The mycosis Cohort number is on in syndrome able second than XXXX. events fungoides, For data Stage of KIRXDLX half data X preliminary In X report reached, cohort the still to expect and moved preliminary of the earlier to enrollment XXXX. non-expressing mycosis is we cohort, enrollment. close Stage to from not the And the having to due to in the next top track due was anticipated. the as second been fungoides half Sézary expected,

I of that out-licensed ongoing potentiate T-cell AstraZeneca. X would head for September lymphoma in you anti-PD-LX X in presented in first into and combination are recap and to neck relapsed advancing are results two efforts. an upon we trials acts remind which XXXX. have at and that currently Phase cancer I peripheral with ESMO wanted checkpoint the ESMO our unresectable in and December and AstraZeneca cell cetuximab Phase monalizumab durvalumab non-small to cancer. activation head you, cell this to lung we randomized like clinical the data update the in with Stage we at pathway one presented trials the is the Finally, X IO Slide have cancer one anti-NKGXA, in On two XXXX on to conducted monalizumab, XX, monalizumab lung combination started To study slide, COAST There On in setting. in neck the NK line

study, three monalizumab For the plus of durvalumab COAST anti-CDXX. the arms the AstraZeneca’s durvalumab evaluated combinations oleclumab, plus and

plus the on showed interim analysis follow versus care results the showed monalizumab primary performed of results XX.X% of versus with a durvalumab for of The XX.X XX.X% alone rate increase for median durvalumab of rate months, response durvalumab durvalumab an confirmed a up monalizumab both XX% an of well overall durvalumab. in the endpoint XX-month results standard shown For PFS After the plus here, arms over respectively. XX% also alone. versus of

On the the or and evaluated right first line frontline anti-tumor cetuximab to study evaluate slide, durvalumab neck in data the head cancer. setting. in chemo-free first Cohort and cancer this the combination triple The activity combination metastatic side the of of neck X demonstrated triplet in monalizumab, head recurrent and

approval based is patients. is and trial. CPS pembro to KEYNOTE-XXX the all-comer monotherapy equal greater As The than plus or of a standard for the chemo off pembrolizumab in reminder, care X in

for this AstraZeneca next We our steps to with collaborate partner continue on potential program.

for oral that has presentation see of are been this Finally, April On XX, late-stage NeoCOAST the for lung an Association overview XXXX in the pleased lung on year. American development Research you see cancer. for we accepted an XX, at to Slide cancer, in Meeting Annual Cancer can monalizumab study

setting and X from Phase durvalumab as chemoradiation Phase not trial, to trial NeoCOAST-X monalizumab to to also Separately, Stages has the that XA and a combination non-small arm AstraZeneca on monalizumab chemotherapy. plus evaluating in Stage clinical the unresectable in NeoCOAST treatment is cancer that X AACR cell the moving with and Phase COAST combination after non-small at in includes have cancer. data, durvalumab a On of data mentioned. cancer concurrent look AstraZeneca lung commenced X based mentioned, forward announced As X lung neck starting therapy. progressed seeing either PACIFIC-X, X a cell it who Phase Slide head with the We XA XX oleclumab

and neck of at IO ESMO first monalizumab line for presented As X cancer. X the from trial in head Phase cetuximab triplet the Cohort plus plus durvalumab mentioned, the data of we

strategic multi-specific plus on cancer to XXXX. the On monalizumab look ESMO Slide call SITC. meetings new partners, Engager up our made have fit-for-purpose as are trial various to platform our treatment. reinforces proprietary molecules X is XX, multi-specific immunity These and we creating against is last candidate AstraZeneca, new neck are ANKET a in further of therapeutics. pipeline, expected technology building cell at engine here. data Engager Additionally, cell NK creating is molecule presented a and an Phase cetuximab expertise scientific cell platform which head presented our pleased latest Eric blocks that including our work of to final be will for multiple This technology tetra-specific versatile in tri several induce space. NK has Vivier further NK potential ongoing ANKET, value with antibody-based to we IO-pretreated class for with the this innovation of that INTERLINK-X entirely stands target We ANKET in illustrated and cancer. an by and year, our

we ANKET platform the have because on data of preclinical for excitement to-date. is the Our brought

NK and harnessing models proliferation First, against the cell in platform cell for cancer. allows of NK function the effector preclinical ANKET

NKPXX the than asset Sanofi. includes efficacy of IL-X by to tetra-specific on the which receptors which is receptors, also and clinic. the enter better complex, Slide due NKpXX/CDXX a activating have for NK with antigen. Second, efficacy trispecific demonstrates This the engagement preclinical tumor the ANKET a lead Overall, we of IL-XR the seen the and clinically NK data at CDXX, antibody. is our SITC first cell the is a molecule the cell it summary gamma based approved IL-XR NK variant, presented preclinical unique anti-tumor cell to On pre-clinically targets specific unique beta XX Engager and XXXX to selected is but

the anti-CDXXX CDXXX against activity see competitor left all which targeted On potent this anti-tumor showing were to IPHXXXX resistant including primary slide, AML, of can a cell trispecific demonstrated the lines, data preclinical ANKET antibody. that AML ADCC you side by

of On efficient effect, release the we a of and that profile pharmacodynamic with in depletion favorable in cell cytokine cells safety the to primate, T expressing engagers. there comparison sustained demonstrate slide, right combining minor is CDXXX nonhuman

an in see we to is the underway tetra-specific yellow, by pleased interleukin green, then portion CDXX; in – the wanted XX, components: and trial Sanofi. interact in our antibody fragment an of the recent We up highlight are red, Phase tumor recognizes Slide will blue a a to that data fragment FC variant the made generation in four X antibody an on that antigen; ANKET, in blue, recognizes with On NKPXX; X. of of that which

show we trispecific black you tetra-specific ANKET the non-alpha-IL-X The vehicle. ANKET of graph ANKET, the left, far graph the the with on the right contribution tetra-specific green with the IL-X on and variant. variant. On a red is graph the systemic is is the left a the The

benefit the tetra-specific green see IL-X can with including You the with the graph, the variant. ANKET

to obinutuzumab. On the as top, the the forward we financials. the you will on toward CDXX ANKET tetra-specific mouse and can with further turn to Activity lung models. is the that middle, for benefit well throughout I right, tetra-specific versus an study. obinutuzumab. on update in as On ANKET, tetra-specific year you on vehicle Frederic updates as seen the not is IND-enabling the see seen obinutuzumab the vehicle, of look the have progress the with bottom, the We in model

Frederic Lombard

and Joyson, you, day, everyone. Thank good

So XX, metrics, moving to position. start one our as cash key our with the usual, finance, of I will Slide

cash of XX, as the December XXXX. million Our we received amounted in of state €XX.X to million December includes loan €XXX.X This guaranteed equivalents cash and XXXX.

are we identifications. In development in remain addition, are resources, We capitalize strategically for and best on ensures that Innate. managing approach vision progress position can we see, read believe can pathways as invest we you that in so debt that our explore in our to to this out our efficiently

in from with will all agreements our received other lines of monalizumab, as the our the of €X.X co-funding assets clinical an by year, release spreading amortized main have can to for on and AstraZeneca only licensing the funding. basis you XXXX is from relating filing, by you increase and separate The impact XXXX. very by press and the mainly to for governmental €XX and monalizumab, performed amortization activity work to in compared of P&L most remind is in company. previous direct Lumoxiti I has the flow. start the into comment the in amounted the as also IPHXXXX showing the which that no discontinued compared in revenue comment you increase Operating that fully and collaboration of Also and R&D classified related and detailed it to expenses intangible at increase the by depreciation non-clinical. recognized operations cash by million, X% upfront compared It the Lumoxiti million lines, mainly was of the XXXX. P&L, mostly on going expenses, characterized decrease has in completion significant and the monalizumab happening I million Now to has amounted of a development remind of resulted €XX.X to XXXX due information. compared income end of company, the to programs from percentage of refer been Note €XX.X last on at payments million I’ll X% revenues were and the year. which expenses. partly €XX.X but to expenses offset an I’ll million, decreasing income, opt-in to to the this line research for revenue paid company AstraZeneca and the the by that acquired

expenses. are to of million fees. increase and G&A in They XXXX here an In to and XXXX, discontinued operations million the mainly million this respectively. of was G&A U.S. excluding $X.X restructuring compared as €XX.X costs relating The to of of increase part AstraZeneca evolving amount were expenses business, the to non-scientific Lumoxiti in amounted for in to composed due paid to XXXX, Turning settlement in be termination million to €X.X equivalent million ancillary expenses to the mainly to €X.X agreement. transition €XX.X these to year the increase related an year. Lumoxiti April

a the contingent These expenses Total on by maximum the have and statements manufacturing actually of to communicated million XXXX a cash estimate that, a cash the this have Mondher. at certain related As including in X% Lumoxiti-related to fund back company strong We at with liability increased has cash operation that costs, Lumoxiti we enough is equivalent operation With to are last a G&A estimated of recap, €XXX.X the end year-on-year. are million XXXX. expecting of costs. XXXX. position discontinued sharing we To financial year. €XX.X its we consolidated reminder, I’m turning planned least to to

Mondher Mahjoubi

you, Thank Slide #XX. to Frederic. move Please

your please. If cell mute, on put you can phone

all we working can to long-term the you XX, across laying our value. as we foundation so see diligently on are and Slide strategic drive are we that execute pillars, to believe Okay,

Looking to number the achieve expect at years. of our clinical milestones program, X a next we over

progress. study heard lacutamab X TELLOMAK from Phase you’ve Joyson, continues As our for to

We data syndrome total expect well half as potentially preliminary data mycosis of as fungoides child report continue second in this to the to year. in from the and Sezary

into you’ve next addition, lymphoma initial year. are the clinic In expected we anti-T heard, moving program our with as data cell

For monalizumab, head early in with we cancer underway. trial clinical look forward neck the lung development to cancer, and further

We adenosine last in we by data presented the preclinical where continue represents continue very to NK from in platform, to In clinic advance Engager. we data forward a next-generation results our this encouraged the We and from platform, look develop of cell at IPHXXXX our the to parallel, technology the anti-CDXX natural believe ANKET our are evolution year. that conferences with we XXXX. agents pathway

trispecific excited XXXX. forward with We our throughout Sanofi on updates ANKET with see look lead proprietary, and ANKET to are the clinic very in the

Let’s #XX. Slide the conclusion move to

build in with company to our positioned you strategy Innate. summary, throughout we made the have the progress meaningful journey value exciting And XXXX future our three stakeholders. patients to tell, across and for can all business and strategic pillars. we for look As continue create at We our

are We updated we across keeping a runway projects a very carefully to can year. strong of and our patients. nearly value that forward our driving deliver our provides have invest in XXXX, position we intimately I’m our into progress managed us with we our medicines We advancing continue cancer our €XXX resources, That very throughout as concludes innovative the Collectively, XXst the have you and XXXX. to to to remarks. look to and which of December so goal million prepared continue pleased on pipeline, business cash

We questions. will now the open to call

Operator

our Daina, please Graybosch from Instructions] your ahead, question Leerink. go Daina is of [Operator first today SVB comes And line open.

Daina Graybosch

of next year? finally you to approval randomized the on connected INTERLINK on fertility monalizumab, MS? MS? to ultimately this milestone study not stage analysis from And taking in a mycosis that that’s for a guys. be three this in one can expect forward? approval next interim moving context the able thanks purpose then of for Pharma would can moving mycosis lacutamab, the Hi, you after KIRXDLX new help you’re all-comers need TELLOMAK, Or for expect the track me in stage? for the the single-arm to Innate you still forward into Maybe And a move what’s payment to other question in the to my fungoides in fungoides, on the to do you. all-comers negative we’re not the questions, lacutamab the AstraZeneca monalizumab. the So cohort lacutamab, when cohort you on confirm into Thank of two get study have me, understand on then confirm On and on second

Mondher Mahjoubi

seen track, the three still happen most we I expecting interim and in half final is line. Daina. you, to presented the year. one, When change are in The by of slide that is third this I’ll second Thank questions. date the answer answer the scheduled interim time Interlink the No you throughout the have on analysis, analysis still of quickly XXXX. for likely end is but XXXX, the to on Joyson this all the

the to on doing this that more bit ask a two are eventually Joyson what maybe to your why provide the we could little the I’m cohort lacutamab, for going details Now the on and questions this a impact bit on Joyson, is of course, little a FDA, you’ve a have our as heard, MS we give so continuous And can dialogue – we strategy. color more registration with have. please.

Joyson Karakunnel

Mondher, you, thank Daina. and you, Thank

cannot these to going two, let so combine me kind I if So feel of questions into to I’m those answer know free questions. please

for this those based were So selecting reminder, just versus patients X X, biopsy a non-expressors, of we as samples. Cohort on Cohort expressors frozen and was when

was a assay based IHC that’s what used tool as we samples, on the selection. So frozen and for

answer to will to lead we cohort, any the are approach. all-comer your an type you since Cohort our going the development diagnostic TELLOMAK this We evaluating integrated anticipate mentioned. delay of into X and be forward, companion similar don’t have is it all-comer of registrational going comprises FFPE That that in to question, approach, first seamlessly that Now connects Cohort patients the this and to as study, X. with cohort

So possible look a and always the I this for always to such, we data. assay is think required we the will believe registration. this in we we time, approach But as overall, at And trial, which are look planning when use be Phase single-arm X FFPE. a for would be registrational this upon would at optimal the dependent

so question. hope especially that readouts And discussions with come I data along. with answers disclose to authorities, more and we health the as soon, continuing X the Phase these hope we’re

Daina Graybosch

the confirm percentage cutoff patients further cohort, confirm are that after it potentially potentially best positive change to the this optimized for is just work just to what slightly So to enrichment. really this yes, may be understand could – because in of new

Joyson Karakunnel

Yes.

So to percentage could total the – change. patients of

we I wouldn’t think it pathway. so in we the between is variation comparison anticipate XX%, there huge around a know what is

Daina Graybosch

you. Thank helpful. you, very very, both. Thank It’s

Mondher Mahjoubi

Thank think from you, Thank Joyson. Daina. you, I second question Yigal. Operator,

Operator

Nochomovitz Yigal Please from ahead. Citi. Yes. go

Unidentified Analyst

taking for question. Thanks Yigal. for on our Carly is this Hi,

believe guess, Thank we’ve first on about segment larger that versus just cancers immunosuppression I on seen rationale you. bit because on more CDXX in the a the a talk Can program. plays types? Is I there specifically. focused in CDXX for focusing others the CDXX other role your the you and tumor HERX-positive evidence cancers? Our is HERX question HERX-positive interested don’t space thoughts in there

Mondher Mahjoubi

you. Thank

again, the rest trying anti-CDXX wanted our Joyson, Before I to of over hand cloud. differentiate to just put this the context to of I into from the

are not first. the We

to are because us latest other actually what potential clinic. understand we trial synergy ideation extremely which into development with over to what in-house course, But a useful totally we not the looked going of we with position we try this differentiate lacutamab. little is same because when and models We dose this on to But our started you up was combination indeed company the the Joyson? we’re delivered at have better hand came to has therapy background in Joyson to classic as up for that, [indiscernible] why learn used help the strategy, the indication more from time, escalation. bit with this give we get now And the for to probably I’m to potential preclinical going cancer. to have at and play

Joyson Karakunnel

questions. the and for you So thanks, thank Mondher,

as of said back to At it Mondher are goes CDXX to quite and aware, all what crowded So landscape, become continues crowded. more to this begin, you currently. the point, is

will go ahead ourselves have the started asked the can least to can how we hand speak ourselves. we over when around when hand that at a to so ourselves, HERX rationale will we CDXX, we So little – for and this I Yannis the But you who bit scientific differentiate – we asked. said started we we this, to development apart. set

based the see the we we this. data that as the had and HERX So with in into we proof NeoCOAST the can COAST mean, in space. we clinical – the went makes in we And landscape to us do space. indication development clinical And of our science, at seen gives we’re ourselves on also which – that think around. come I study, Mondher how have you’ll now CDXX CDXX thinking utilizing the how COAST mentioned, can data looked optimize I another the the Afterwards, CDXX some

HERX. around about So bit the Yannis can the over maybe little I’ll speak it science to a who hand

Yannis Morel

opposed Yes. and Joyson. oleclumab. in because differentiating are our like Thank especially CDXX actually the we molecule antibody said, that our you, to increasing you Yes, development inhibitors of are properties, as its other first

Our are said important meaning to it the sector, by continued the like antibody that high dose, molecule of Joyson, meaning and it also we for which is enzyme surface block blocking does the are not was an not CDXX, to blocking that HERX the enzyme. also explored even very differentiate effect, based the others. we soluble going we on but antibody. resistance at was And actually have Others mediating assets the into of is of the of were combination. PDX to CDXX that preclinical – our that development important combination ADCT data combination mediating is by CDXX mostly And exploring targeting have

models. So, can that by of preclinical combining in the the blockade efficacy CDXX of increase trastuzumab

Unidentified Analyst

there any milestones PACIFIC-X Got on Innate Okay. PACIFIC-X? one are And Thanks. AstraZeneca other really payment from the That’s tied to should aware start of it. helpful. just then And be that housekeeping of? question. Did we receive a milestone

Mondher Mahjoubi

Yes.

everyone still being study we of excited wait maybe to course, that So, PACIFIC-X patient again, remind that we started. has of And first course, are, their dosed.

granularity potentially have We minor not on stocks. provided

rate activity part milestones, well and as and is payment we as achieved. could another first the so receive far you. the payment a on of AstraZeneca. predefined in fall started commercial million which regulatory total, In an have also Phase And the the million XXXX. X in €XX in €XX interim double-digit a million, €XXX the We million will INTERLINK-X, of of €XXX with received trigger million about €XXX if Thank potentially analysis developing royalty

Unidentified Analyst

the for questions. Thanks great. Okay, taking

Mondher Mahjoubi

you. Thank

Operator

comes please our you. from Thank Liisa, next of Liisa And go Evercore Bayko question ISI. ahead.

Your line is open.

Liisa Bayko

Hi there. Thanks taking for questions. my

analysis this year? interim INTERLINK are of planning for you First one, an

Mondher Mahjoubi

thank Liisa, you for your the questions. Hi joining and call

by conducted this patient interim the – to have an being XX to AstraZeneca months enrolled. know, first XX is is was you the performed to trial months after As and about analysis is plan

in second November the of half is so was XXXX. the patient for XXXX, expected enrolled The first interim

Liisa Bayko

Wonderful.

JPMorgan alone? that discuss Great. going to this more strategy think with Are you sort specifically MF. then for you there just syndrome? do of maybe might indication discuss. was you regulatory Sézary some can you just Maybe can combination a Okay. at some I Thanks. file for And little mention bit about your

Mondher Mahjoubi

absolutely. Yes,

think have way registration the again, to interaction MF/Sézary our we hand a with question? it’s recap syndrome over I good FDA. this the strategy to based you Joyson address please can upon, to Joyson,

Joyson Karakunnel

the thank Thanks and Mondher question. you for

at start me our initial least with let strategy. So, off

that strategy fact, So, on this a have present data was fast-to-market about cohort do ongoing looking Sézary strategy. pivotal the are that our for year. to And in initial – we is later we

your a mogamulizumab of possibility question both is take as provide know, So, that MF, of that SS both cohort as MF. label is we the is and still registrational To as well option, pathway. another combining what another SS potential does you many and ongoing about the which is approach

So, for indications. combining precedent there is of these both

are we for path. to – are to be able aligned registrational a we having we regulators the with also with also make all at registrational the the well pathway. in as sure ongoing addition, well discussions to they possible that European So, options FDA But are the as options as be as have health looking

Liisa Bayko

some might that, Okay. it when really data Any is or more on dependent? granularity you have idea

Joyson Karakunnel

well as will be data dependent. be as as It about presenting mentioned, data this is mycosis – we And fungoides later it year. Sézary will syndrome so we

Liisa Bayko

Thanks a lot.

Mondher Mahjoubi

you. Thank

Operator

of our Parekh Goldman next please Keyur And Thank Keyur, question ahead. you. go from Sachs. comes

Your open. line is

Keyur Parekh

tetra kind you, Two, kind you guys MF, And get how wondering to of me peak than kind Hi. if doing of Thank across you please. kind developing how the of drug most both you Sézary can and One, if as about for how think do think my you – can questions. indication. then you for these opportunity taking think oncology just as think syndrome big indications been quickly may, and you sizes Mondher, I might kind remind of be the about to for just the this That’s number have kind you of products, longer be development you ANKET question one. revenue able separately people. of

Just opportunities of challenges help us what you about might think be. and some the the think

safety have a We struggle variability of the perspective. seen bi-specifics all from kind

tolerability we what something should profile that means and Thank targeting the us So, just if you five are kind agents. having be perspective of these help through think targets, for that is the of you. the doing it different from on focus

Mondher Mahjoubi

and will Thank as you, answer Keyur. Great try as precise possible. clear questions. to as I

so on maybe and we and top data have all, that of for five first EU. Sézary is – the So, MF, U.S.

patients. They are to And okay, So, a think indication. significant they one therapy. XXX start if the less and having it’s think long idea. syndrome in really And old. XX% quite There point XX% live nevertheless, they a at about and market. say, get XXX all-in-all, an actually But Sézary about of than to so you about multiple of niche have roughly, every longer new it’s this lines year, to it’s let’s I received X,XXX time, it’s prevalence patient PFS, so

really T-cell So, quickly small very But the there proof actually on please difficult market also population. side cutaneous market of And day are to in it’s some on to lymphoma. really It’s opportunity. a such is cutaneous XX% concept business. of all that as mind heterogenous sophisticated T-cell a as just knew half about It’s heterogenous. from of it are and And mycosis a of way one that keep is know type of fungoides. lymphoma a About mycosis much quite to it’s and And registration classification. get T-cell Sézary Sézary is one. challenging work do We we fungoides. lymphoma not and which bigger very to cutaneous possible, are subtypes MF one

overall new a huge lymphoma to is And maybe a which not why to mycosis of bigger is we fungoides. one. that’s compare after lymphoma, the peripheral T-cell So, we you cutaneous much year. very when about All-in-all, every course, clearly, it market talking elected patients X,XXX to opportunity, T-cell are go X,XXX

half are talking and express target. XX,XXX the them every nearly of new year, about We patients

have But started much indication. say, it’s have not So a would year. do again, I we I we side maybe, give just too ambitious about We a early we results. data there. you commercial followed are from thinking in last be the strategy. number, the too bigger and the may it would clearly, is If you my at full benchmark year because very good our mogamulizumab. But potential looked And a

sold about which moga, €XXX million main is and Sézary. they So, indication for if MF

in everywhere not So reimbursed Europe. Europe, as lymphoma. approved is clearly, U.S. a in the there is but the mogamulizumab you know, cutaneous it’s in within and T-cell business And there

in was the drug a approved just have in of And of U.S. we and Europe. So, XXXX of in course, penetration. XXXX market challenge, end terms the in

about nevertheless, hope quite it market clarified comes Sézary. a still when it’s I question. to But indicator new. I I think it’s So, good and opportunity MF the this first

and I our into thinking for think product develop IND-enabling as to this how us figure second to of really clinic, actually the antibodies. studies actually question is your a and generation really proprietary to position how why out about ANKET what multi-specific how progressing it and are do we new preparing trying every we drug day

strategy engager. think also results using actually could engaging already main could we reserves the think we active good combining I especially NK-cell pathway from T-cell the that reason an seen cells, engager the quite versus be amazing, the And way have to be into to tumors. in with could the safety you combination for others have this of opportunity fresh that data but antibody afford. an one And actually, opportunity also into a liquid differentiate, a cells of are

course, usually, the this And some on you small. idea X. talking it’s Phase are combination. you nevertheless, But of about provide Of potential X,

the solid with we but of great Last can that screen I there pretty terms only I think working make target far. so that again, tumors manufacturing. to there it’s resides we tumors. not impacted least, main a And with do but the to prepared the sure and engaging this on that it’s potential opportunity. it’s ones significant not space, only to and in is as tumor solid the CMC And is tackle not opportunity one the antibodies that think brand-new believe solid I one, if is how the sense are our is in construct, and the challenge, of a is same.

there top once an is So, the we because first that are it’s get this we antibody But where overcome into clinic, develop antibody. have the remember, such to of that, we that time on there complex challenges included IMC.

Of data. same benefits a profile. safety into translates with to without And NK-cells purpose downside are course, sure of so that clinic we We the issue these and make selected can the this the the the that IL-X the far encounter. to for same need course, you safety expand variant preclinical

that are clinical we have two data at to various generated whether So, we the patients. can translate these but for we kind short-term go will through, so last have the in main what benefit tell presented clinical challenges meetings real of far what year and

development context think the NK into perspective. I but maybe So, in long sorry strategy put to opportunity for a good our platform it’s answer,

Keyur Parekh

Thank Mondher. very That’s helpful. you,

Mondher Mahjoubi

Thank next welcome. You’re question. you, Keyur. Operator,

Operator

Instructions] [Operator Swayampakula H.C. comes Wainwright. from next ahead. Swayampakula, go And our question Ramakanth please from

Your line is open.

Swayampakula Ramakanth

Mondher. Thank been asked, my you. Most have of questions

antibody, in on the say here XXXX, you be terms or is next from steps the potentially any have the However, make to anti-CDXX in developed it AstraZeneca has the program decision, are, what of how will the onwards? do who

Mondher Mahjoubi

Hi you and RK. agreements Good your to agreement. to question. with you similar CDXX AstraZeneca look thank have for monalizumab the license

really and where of it’s So, in development also engaged a we we agreement co-development, co-commercialization are the are policy. involved, this

we the, now opposed then agent learning nevertheless, trial, development of of said, the of antibody. planning and of They tackling the we in the I the But think course, single or from, call a on I are development next in in AstraZeneca AstraZeneca with milestone proof-of-concept the as objective escalation, the an did And these whatever for part and phase X. pathway, combination. again, was, because the milestone it’s COAST Phase which discussion first CDXX. reached the the step, demonstration it, important you

from and learning this position and the in differentiate collaboration. are CDXX on we competition, how best discussing AstraZeneca partnership, in of and that from with doing to the are So, we rest

Swayampakula Ramakanth

Mondher. you, Thank

Mondher Mahjoubi

Thank you, RK.

Operator

you. Thank

We Mondher. further call no will you, questions. over the I have to hand back

Mondher Mahjoubi

core portfolio both of year our ahead, just you stage the and multiple value, present our near-term and continue highlighting to And hope we I we it’s will These are our we center program. XXXX. execute both for looking long-term a a think to against I Again, readouts results you. as priority while appreciate, from and – programs. Thank advance our strength reminder, results for lacutamab of could continue And depth development proprietary delivering as also R&D. great opportunity full reported strategic partnered to

thank the early-stage Bye-bye. you engine. our move platform to of call. development of its clinical our you. the of which strategy What head we our continue R&D the and R&D from neck in I you the wonderful for activity in and this and participation business clinic with force to your wish forward well that building course towards with to early lung a for underway, said, generation a enough, will We cancer Thank cancer next with sustainable day, look ANKET show

Operator

concludes this Thank joining. gentlemen, today’s and all you. you for Thank Ladies call.

You may now disconnect your lines.

Innate Pharma (IPHA) 24 Mar 222021 Q4 Earnings call transcript